Latest Iperion (NZX:IPR) News

Page 1

Page 1 of 1

Iperion narrows loss with waived licence targets and secured loan facility

Iperion narrows loss as Pathoglaze licence targets waived and loan facility secured

Iperion Limited trimmed its net loss to $294,595 for the year to March 2026, aided by waived manufacturing fees and waived licence performance targets, while securing a $250,000 loan facility to underpin ongoing development of its antimicrobial Pathoglaze product.

Victor Sage

1 July 2026